References

1. Frielle T, Daniel KW, Caron MG, Lefkowitz RJ. (1988) Structural basis of beta-adrenergic receptor subtype specificity studied with chimeric beta 1/beta 2-adrenergic receptors. Proc Natl Acad Sci U S A, 85: 9494-9498. [PMID:2849109]

2. Hoffmann C, Leitz MR, Oberdorf-Maass S, Lohse MJ, Klotz KN. (2004) Comparative pharmacology of human beta-adrenergic receptor subtypes - characterization of stably transfected receptors in CHO cells. Naunyn Schmiedebergs Arch Pharmacol., 369: 151-159. [PMID:14730417]

3. Mejean A, Guillaume JL, Strosberg AD. (1995) Carazolol: a potent, selective beta 3-adrenoceptor agonist. Eur J Pharmacol., 291: 359-366. [PMID:8719421]

4. Molenaar P, Sarsero D, Arch JR, Kelly J, Henson SM, Kaumann AJ. (1997) Effects of (-)-RO363 at human atrial beta-adrenoceptor subtypes, the human cloned beta 3-adrenoceptor and rodent intestinal beta 3-adrenoceptors. Br J Pharmacol, 120: 165-176. [PMID:9117106]

5. Popp BD, Hutchinson DS, Evans BA, Summers RJ. (2004) Stereoselectivity for interactions of agonists and antagonists at mouse, rat and human beta3-adrenoceptors. Eur J Pharmacol., 484: 323-331. [PMID:14744619]

6. Sato Y, Kurose H, Isogaya M, Nagao T. (1996) Molecular characterization of pharmacological properties of T-0509 for beta-adrenoceptors. Eur J Pharmacol., 315: 363-367. [PMID:8982677]

7. Strosberg AD. (1997) Structure and function of the beta 3-adrenergic receptor. Annu Rev Pharmacol Toxicol., 37: 421-450. [PMID:9131260]